Clinical Trial: Self-Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD) (SERRA-I Study)

U.S., May 28 -- ClinicalTrials.gov registry received information related to the study (NCT06991322) titled 'Self-Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD) (SERRA-I Study)' on May 19.

Brief Summary: VahatiCor's Coronary Sinus Reducer (A-FLUX) has been designed to improve angina or angina-like symptoms in patients with CMD. SERRA-I is an early feasibility study that evaluates the safety and clinical performance of the A-FLUX Reducer in this population.

Study Start Date: May, 2025

Study Type: INTERVENTIONAL

Condition: Coronary Microvascular Dysfunction Coronary Microvascular Disease

Intervention: DEVICE: A-FLUX Reducer System

The VahatiCor A-FLUX Reducer System is an implanta...